First‐in‐human study of CPL207280, a novel G‐protein‐coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration

• Published in: Diabetes, obesity & metabolism Vol. 26; no. 4; pp. 1376 - 1385
• Main Authors: Bazydło‐Guzenda, Katarzyna, Jarus‐Dziedzic, Katarzyna, Gierczak‐Pachulska, Agnieszka, Buda, Paweł, Rudzki, Piotr J., Buś‐Kwaśnik, Katarzyna, Juszczyk, Ewelina, Tratkiewicz, Ewa, Rabczenko, Daniel, Segiet‐Święcicka, Agnieszka, Wieczorek, Maciej
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.04.2024; Wiley Subscription Services, Inc
• Subjects: Agonists; Body mass index; Diabetes; Diabetes mellitus (non-insulin dependent); drug development; Food intake; Glucagon; GPR40/FFAR1; Hepatotoxicity; Insulin; Metformin; Pharmacodynamics; Pharmacokinetics; phase I–II study; Safety; type 2 diabetes; drug development; pharmacokinetics; phase I-II study; type 2 diabetes; GPR40/FFAR1; pharmacodynamics
• DOI: 10.1111/dom.15439
• ISSN: 1462-8902

Aim To assess the safety, tolerability and pharmacokinetic (PK) profile of single and multiple doses of CPL207280, a new G‐protein‐coupled receptor 40 agonist developed to treat type 2 diabetes (T2D). Methods The phase 1 study in healthy volunteers (White, age 18–55 years, body mass index 18.5–29.9 kg/m2) was performed after single (24 subjects, 5–480 mg) and multiple (32 subjects, 60–480 mg) once‐daily administration of CPL207280.  The effect of food intake and interaction with metformin were evaluated in additional cohort (12 subjects, 120 mg). The primary objective was the safety and tolerability of CPL207280. Secondary objectives included PK and pharmacodynamic (PD) characteristics (glucose, insulin, C‐peptide, proinsulin, glucagon levels) observed during the 14‐day treatment period. Results No deaths or serious adverse events (AEs) were reported. All reported AEs were classified as unrelated to the study product. No clinically significant differences in safety parameters were observed between cohorts and no food or metformin effect on safety parameters was identified. The ascending dose of CPL207280 caused an increase in the PK parameters maximum observed plasma concentration (Cmax) or area under the plasma concentration–time curve up to 24 h. However, dose‐normalized Cmax decreased with ascending dose. There was no relationship between the CPL207280 dose or prandial state and terminal elimination half‐life and terminal elimination rate constant. No clear relationship between CPL207280 dose and PD area under the effect curve values was observed. Conclusions CPL207280 was found to be safe and well tolerated by healthy volunteers (with a low risk of hepatotoxicity) for up to 14 days of administration. The PK profile of CPL207280 supports single‐daily administration and justifies further development of this therapy for patients with T2D.